The complex problem of left ventricular hypertrophy (LVH) related to systemic arterial hypertension (H) has motivated several experimental, clinical and epidemiological studies. Because LVH is an important predisposing factor for heart failure 1 and because it is physiopathologically related to ischemic heart disease and ventricular arrhythmias, hypertensive left ventricular hypertrophy is an i...

Introduction: The aim of the study was to investigate the structural and hemodynamic changes as well as cardiac transcriptional profile of the key regulatory proteins, sirtuins family (SIRT1-7), in adaptive and mal-adaptive phases of left ventricular hypertrophy (LVH). Methods: LVH was induced in male Wistar rats (190±20g) by abdominal aortic banding. The third and sixteenth weeks post-surgery ...

Echocardiograms were obtained on 27 adults with electrocardiographic criteria of left ventricular hypertrophy (LVH) to determine how echocardiograms might best identify LVH. Both the left ventricular (LV) posterior wall thickness and interventricular septal thickness were found by echocardiography to be increased (greater than or equal to 12 mm) in only 13 of 27 patients (48%) with LVH. The LV ...

BACKGROUND Calcium calmodulin-dependent kinase II (CaMKII) can be more active in patients with left ventricular hypertrophy (LVH), which in turn causes phosphorylation of ryanodine receptors, resulting in inactivation and the instability of intracellular calcium homeostasis. The present study aimed to determine the effect of CaMKII-ryanodine receptor pathway signaling in rabbits with left ventr...

Left ventricular hypertrophy (LVH) is the adaptative mechanism of the heart to systolic overload of the left ventricle. Nevertheless, LVH plays a role in some complications, such as cardiac arrhythmias. Patients with LVH are more likely to develop ventricular arrhythmias than the hypertensive population without LVH. Further, the relation between left ventricular mass and ventricular arrhythmias...

Obesity is directly and strongly associated with hypertension and left ventricular hypertrophy (LVH). Development of LVH is multifactorial, caused both by haemodynamic and non-haemodynamic factors. Hypertension is the main haemodynamic factor. Humoral mechanisms, as a non-haemodynamic factor for LVH development, have not been completely explained. The aim of this study is to determine whether h...

Growth differentiation factor-15 (GDF-15) has been identified as an endogenous anti-hypertrophy effect. However, the association of plasma GDF-15 levels with left ventricular hypertrophy (LVH) in hypertension is poorly understood. We investigate the effect of plasma GDF-15 levels on left ventricular hypertrophy (LVH) in hypertension. We measured the plasma levels of GDF-15 in 299 untreated hype...

Athletes commonly develop what is regarded as a benign increase in cardiac mass in response to physical training. However, prolonged training may lead to a degree of cardiac remodeling that mimics hypertrophic cardiomyopathy (HCM). Left ventricular hypertrophy (LVH) can be defined echocardiographically as a left ventricular wall thickness (LVWT) of greater than 12mm. A LVWT of 12-16mm represent...

Left ventricular hypertrophy (LVH) is prevalent and associated with a poor long-term prognosis. The Framingham Heart Study, for example, showed that LVH was present in 15–20% of adults, and that, for each 50 g/m increment of left ventricular mass, the relative risk of cardiovascular death increased by 1.73 in men and 2.12 in women. Although hypertension, obesity and valvulopathies account for m...